Haplo Cord Transplantation – The Best of Both Worlds
Haplo-cord transplantation combines infusion of an umbilical cord blood unit with CD34 selected cells usually from HLA mismatched related donors. Initial rapid count recovery results from the haplo-identical hematopoietic progenitors, which in the majority of cases are gradually replaced by durable engraftment from umbilical cord blood progenitors. UCB grafts used for haplo-cord tend to be smaller, but better matched than those required for single or double UCB SCT. Over 200 patients with hematological malignancies have been transplanted at two institutions. (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 24, 2016 Category: Hematology Authors: Koen van Besien, Richard Childs Source Type: research
Matched unrelated donor transplants – State of the art in the 21st century
Haematopoietic stem cell transplantation (HSCT) is the therapy of choice in many haematological malignant and non-malignant diseases by using human leucocyte antigen (HLA)-matched siblings as stem cell source but only one third of the patients will have HLA-matched siblings. Hence, physicians rely on the availability of matched unrelated donors (URD). The possibility of finding a matched URD is now more than 70% due continuous expansion of URD registries around the world. The use of URD in adult patients is steadily increasing and in the last 8 years, has superseded the numbers of matched sibling donor transplants and has ...
Source: Seminars in Hematology - July 24, 2016 Category: Hematology Authors: Syed Y. Altaf, Jane F. Apperley, Eduardo Olavarria Source Type: research
outside front cover
(Source: Seminars in Hematology)
Source: Seminars in Hematology - June 30, 2016 Category: Hematology Source Type: research
Masthead
(Source: Seminars in Hematology)
Source: Seminars in Hematology - June 30, 2016 Category: Hematology Source Type: research
Table of Contents
(Source: Seminars in Hematology)
Source: Seminars in Hematology - June 30, 2016 Category: Hematology Source Type: research
Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients
To the Editor: (Source: Seminars in Hematology)
Source: Seminars in Hematology - June 17, 2016 Category: Hematology Authors: Pierre Peterlin, Thierry Guillaume, Jacques Delaunay, Mohamad Mohty, Alice Garnier, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Maud Voldoire, Cyrille Touzeau, Cecile Chauvin, Thomas Gastinne, Marie C B éné, Steven Le Gouill, Philippe Moreau, Patric Tags: Letter to the Editor Source Type: research
Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients
To the Editor (Source: Seminars in Hematology)
Source: Seminars in Hematology - June 17, 2016 Category: Hematology Authors: Pierre Peterlin, Thierry Guillaume, Jacques Delaunay, Mohamad Mohty, Alice Garnier, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Maud Voldoire, Cyrille Touzeau, Cecile Chauvin, Thomas Gastinne, Marie C Béné, Steven Le Gouill, Philippe Moreau, Patrice Tags: Letter to the Editor Source Type: research
Hodgkin lymphoma in the elderly, pregnant, and HIV-infected
Hodgkin lymphoma (HL) presenting in patients with co-incidental advanced age, pregnancy, or human immunodeficiency virus (HIV) infection is uniquely challenging to manage. In this article we integrate recent evidence and clinical expertise to present recommendations for diagnosis and therapeutic management. Older patients with HL need to be carefully evaluated for comorbidies after which judicious choice of chemotherapy should minimize functional compromise. A pregnant patient with concurrent HL should be staged with minimal use of imaging requiring ionizing radiation and treated in an individualized manner optimally combi...
Source: Seminars in Hematology - May 16, 2016 Category: Hematology Authors: Veronika Bachanova, Joseph M. Connors Source Type: research
Hodgkin lymphoma in the elderly, pregnant, and HIV infected
Hodgkin lymphoma (HL) presenting in patients with co-incidental advanced age, pregnancy or HIV infection is uniquely challenging to manage. In this article we integrate recent evidence and clinical expertise to present recommendations for diagnosis and therapeutic management. Older patients with HL need to be carefully evaluated for comorbidies after which judicious choice of chemotherapy should minimize functional compromise. A pregnant patient with concurrent HL should be staged with minimal use of imaging requiring ionizing radiation and treated in an individualized manner optimally combining the strategies of treatment...
Source: Seminars in Hematology - May 16, 2016 Category: Hematology Authors: Veronika Bachanova, Joseph M. Connors Source Type: research
Hodgkin lymphoma: Pathology and biology
The Hodgkin and Reed-Sternberg (HRS) tumor cells of classical Hodgkin lymphoma (HL), as well as the lymphocyte predominant (LP) cells of nodular lymphocyte predominant HL (NLPHL), are derived from mature B cells. However, HRS cells have largely lost their B-cell phenotype and show a very unusual expression of many markers of other hematopoietic cell lineages, which aids in the differential diagnosis between classical HL (cHL) and NLPHL and distinguishes cHL from all other hematopoietic malignancies. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 12, 2016 Category: Hematology Authors: Stephan Mathas, Sylvia Hartmann, Ralf K üppers Source Type: research
Nodular lymphocyte-predominant Hodgkin lymphoma
(NLPHL) is a rare subtype of Hodgkin lymphoma with distinct clinicopathologic features. It is typified by the presence of lymphocyte predominant (LP) cells, which are CD20+ but CD15 – and CD30– and are found scattered amongst small B lymphocytes arranged in a nodular pattern. Despite frequent and often late or multiple relapses, the prognosis of NLPHL is very favorable. There is an inherent risk of secondary aggressive non-Hodgkin lymphoma (NHL) and studies support that ris k is highest in those with splenic involvement at presentation. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 12, 2016 Category: Hematology Authors: Kerry J. Savage, Anja Mottok, Michelle Fanale Source Type: research
Hodgkin lymphoma: Pathology and Biology
The Hodgkin and Reed-Sternberg (HRS) tumor cells of classical Hodgkin lymphoma (HL), as well as the lymphocyte predominant (LP) cells of nodular lymphocyte predominant HL (NLPHL) are derived from mature B cells. However, HRS cells have largely lost their B cell phenotype and show a very unusual expression of many markers of other hematopoietic cell lineages, which aids in the differential diagnosis between classical HL (cHL) and NLPHL and distinguishes cHL from all other hematopoietic malignancies. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 12, 2016 Category: Hematology Authors: Stephan Mathas, Sylvia Hartmann, Ralf Küppers Source Type: research
Nodular lymphocyte predominant Hodgkin lymphoma
(NLPHL) is a rare subtype of Hodgkin lymphoma (HL), accounting for ∼5% of all HL. Patients with NLPHL typically present with asymptomatic early stage disease with peripheral lymph node involvement. Unlike classical Hodgkin lymphoma (cHL), late and often multiple relapses have been widely reported [1] but despite this, the prognosis is generally favourable with deaths due to NLPHL extremely uncommon. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 12, 2016 Category: Hematology Authors: Kerry J. Savage, Anja Mottok, Michelle Fanale Source Type: research
Hodgkin lymphoma: Introduction
We would like to welcome you to this issue of Seminars in Hematology on Hodgkin lymphoma. Hodgkin lymphoma was described by Thomas Hodgkin more than 175 years ago and has since become one of the best curable malignancies today. This progress is largely due to advances in radiotherapy and the development of effective multi-agent chemotherapy [1 –5]. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Andreas Engert, Theodoros P. Vassilakopoulos Source Type: research
Prognostic factors in Hodgkin lymphoma
During the last decades, the prognosis of Hodgkin lymphoma (HL) has been improved significantly with the introduction of effective chemotherapy and the implementation of risk-adapted treatment approaches. Identification of reliable risk factors is crucial to guide treatment over the course of disease. Both clinical and biological factors have been implicated in the prognosis of HL and are often used in prognostic scores to discriminate risk groups. To prevent under- or overtreatment, patients are usually assigned to one of the three widely established risk groups for first-line treatment, based solely on clinical risk fact...
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Paul J. Br öckelmann, Maria K. Angelopoulou, Theodoros P. Vassilakopoulos Source Type: research
